Back to Newsroom

DALCOR ACHIEVES 50 PERCENT ENROLLMENT MILESTONE FOR PHASE 3 CARDIOVASCULAR TRIAL

DalCor Pharmaceuticals today announced it has exceeded its enrollment schedule with 50 percent of patients randomized in its Phase 3 “dal- GenE” clinical trial. More than 2,500 out of 5,000 expected patients with acute coronary syndrome (ACS) and the AA genotype at variant rs1967309 in the ADCY9 gene have entered into this cardiovascular outcomes study of dalcetrapib. In 2012, investigators at The Montreal Heart Institute observed a significant association of dalcetrapib in altering cardiovascular events (CV) for the AA genotype patients who had a 39 percent reduction in cardiovascular events when compared with placebo.
READ MORE…